IL112134A - Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them - Google Patents

Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them

Info

Publication number: IL112134A
Authority: IL; Israel
Prior art keywords: hydrogen; 4alkyl; substituted; halogen; optionally substituted
Prior art date: 1993-12-29

Application number

IL11213494A

Other languages

English (en)

Other versions

IL112134A0 (en

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-29

Filing date

1994-12-23

Publication date

1999-12-22

1993-12-29 Priority claimed from GB9326480A external-priority patent/GB9326480D0/en

1994-04-12 Priority claimed from GB9407189A external-priority patent/GB9407189D0/en

1994-04-22 Priority claimed from GB9408065A external-priority patent/GB9408065D0/en

1994-08-15 Priority claimed from GB9416428A external-priority patent/GB9416428D0/en

1994-12-23 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

1995-03-15 Publication of IL112134A0 publication Critical patent/IL112134A0/xx

1999-12-22 Publication of IL112134A publication Critical patent/IL112134A/xx

Links

150000002780 morpholines Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 5
239000001257 hydrogen Substances 0.000 abstract 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
229910052736 halogen Inorganic materials 0.000 abstract 3
150000002367 halogens Chemical class 0.000 abstract 3
150000002431 hydrogen Chemical class 0.000 abstract 3
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
206010047700 Vomiting Diseases 0.000 abstract 1
125000004103 aminoalkyl group Chemical group 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Psychiatry (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL11213494A 1993-12-29 1994-12-23 Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them IL112134A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB9326480A GB9326480D0 (en)	1993-12-29	1993-12-29	Therapeutic agents
GB9407189A GB9407189D0 (en)	1994-04-12	1994-04-12	Therapeutic agents
GB9408065A GB9408065D0 (en)	1994-04-22	1994-04-22	Therapeutic agents
GB9416428A GB9416428D0 (en)	1994-08-15	1994-08-15	Therapeutic agents

Publications (2)

Publication Number	Publication Date
IL112134A0 IL112134A0 (en)	1995-03-15
IL112134A true IL112134A (en)	1999-12-22

Family

ID=27451102

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL11213494A IL112134A (en)	1993-12-29	1994-12-23	Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them

Country Status (24)

Country	Link
US (1)	US5612337A (de)
EP (3)	EP1462450B1 (de)
JP (2)	JP3071467B2 (de)
KR (1)	KR100286412B1 (de)
CN (1)	CN1067683C (de)
AT (3)	ATE364606T1 (de)
BG (1)	BG62616B1 (de)
BR (1)	BR9408442A (de)
CA (1)	CA2178219C (de)
CZ (1)	CZ288176B6 (de)
DE (3)	DE69434991T2 (de)
DK (1)	DK0737192T3 (de)
ES (1)	ES2164758T3 (de)
HU (1)	HU221139B1 (de)
IL (1)	IL112134A (de)
LV (1)	LV11687B (de)
NO (1)	NO307090B1 (de)
NZ (1)	NZ277839A (de)
PL (1)	PL181214B1 (de)
RU (1)	RU2131426C1 (de)
SG (1)	SG52217A1 (de)
SK (1)	SK283070B6 (de)
TW (1)	TW449588B (de)
WO (1)	WO1995018124A1 (de)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5719147A (en) *	1992-06-29	1998-02-17	Merck & Co., Inc.	Morpholine and thiomorpholine tachykinin receptor antagonists
EP0758329A1 (de) *	1994-05-05	1997-02-19	MERCK SHARP & DOHME LTD.	Morpholin-derivate und deren verwendung als antagonisten von tachykininen
ES2157337T3 (es) *	1994-08-15	2001-08-16	Merck Sharp & Dohme	Derivados de morfolina y su uso como agentes terapeuticos.
GB9417956D0 (en) *	1994-09-02	1994-10-26	Merck Sharp & Dohme	Therapeutic agents
GB9426104D0 (en) *	1994-12-23	1995-02-22	Merck Sharp & Dohme	Use of surfactants and emulsions
GB9505491D0 (en) *	1995-03-18	1995-05-03	Merck Sharp & Dohme	Therapeutic agents
GB9513972D0 (en) *	1995-07-08	1995-09-06	Merck Sharp & Dohme	Pharmaceutical compositions
GB9523244D0 (en) *	1995-11-14	1996-01-17	Merck Sharp & Dohme	Therapeutic agents
US5891875A (en) *	1996-05-20	1999-04-06	Eli Lilly And Company	Morpholinyl tachykinin receptor antagonists
EP0912174B1 (de) *	1996-07-17	2004-04-28	MERCK & CO., INC.	Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten
US6117855A (en)	1996-10-07	2000-09-12	Merck Sharp & Dohme Ltd.	Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
CA2273785A1 (en) *	1996-12-02	1998-06-11	Raymond Baker	Use of nk-1 receptor antagonists for treating severe anxiety disorders
EP0942728A1 (de) *	1996-12-02	1999-09-22	MERCK SHARP & DOHME LTD.	Die verwendung von nk-1 rezeptor antagonisten für die behandlung von sexuellen fehlfunktionen
EP0941093B1 (de) *	1996-12-02	2005-02-09	MERCK SHARP & DOHME LTD.	Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden
US6613765B1 (en)	1996-12-02	2003-09-02	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating major depressive disorders
ES2234039T3 (es) *	1996-12-02	2005-06-16	MERCK SHARP & DOHME LTD.	Uso de antagonistas del receptor nk-1 para tratar trastornos de depresion mayor.
WO1998024444A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating substance use disorders
US6114315A (en) *	1996-12-02	2000-09-05	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
WO1998024447A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating cognitive disorders
PT942729E (pt) *	1996-12-02	2004-12-31	Merck Sharp & Dohme	Utilizacao de antagonistas de receptores nk-1 para tratamento de doencas do stresse
WO1998024443A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating bipolar disorders
WO1998024446A1 (en) *	1996-12-02	1998-06-11	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating movement disorders
US6100256A (en) *	1996-12-02	2000-08-08	Merck Sharp & Dohme Ltd.	Use of NK-1 receptors antagonists for treating schizophrenic disorders
EP0942735A1 (de) *	1996-12-02	1999-09-22	MERCK SHARP & DOHME LTD.	Die verwendung von nk-1 rezeptor antagonisten für die behandlung von schizophrenischen störungen
US5977104A (en) *	1996-12-02	1999-11-02	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating bipolar disorders
GB9700555D0 (en) *	1997-01-13	1997-03-05	Merck Sharp & Dohme	Therapeutic agents
CA2287487A1 (en) *	1997-04-24	1998-10-29	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating eating disorders
CA2298777A1 (en) *	1997-08-04	1999-02-18	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating mania
CA2298779A1 (en) *	1997-08-04	1999-02-18	Merck Sharp & Dohme Limited	Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
GB9716463D0 (en) *	1997-08-04	1997-10-08	Merck Sharp & Dohme	Therapeutic agents
GB9716457D0 (en) *	1997-08-04	1997-10-08	Merck Sharp & Dohme	Therapeutic agents
US6156749A (en) *	1997-12-01	2000-12-05	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating movement disorders
US6271230B1 (en)	1997-12-01	2001-08-07	Merck Sharp & Dohme Limited	Use of NK-1 receptor antagonists for treating cognitive disorders
US6087348A (en) *	1997-12-01	2000-07-11	Merck Sharp & Dohme Ltd.	Use of NK-1 receptor antagonists for treating stress disorders
US5972938A (en) *	1997-12-01	1999-10-26	Merck & Co., Inc.	Method for treating or preventing psychoimmunological disorders
GB9810092D0 (en) *	1998-05-11	1998-07-08	Merck Sharp & Dohme	Therapeutic agents
GB9812662D0 (en) *	1998-06-11	1998-08-12	Merck Sharp & Dohme	Therapeutic use
GB9812617D0 (en) *	1998-06-11	1998-08-12	Merck Sharp & Dohme	Therapeutic use
WO1999064010A1 (en) *	1998-06-11	1999-12-16	Merck Sharp & Dohme Limited	Use of a nk-1 receptor antagonist for treating psychiatric disorders
EP1085873A1 (de) *	1998-06-11	2001-03-28	MERCK SHARP & DOHME LTD.	Vewrwendung von nk-1 rezeptor antagonisten zur behandlung von psychiatrischen krankheiten
GB9812664D0 (en) *	1998-06-11	1998-08-12	Merck Sharp & Dohme	Therapeutic use
GB9813025D0 (en)	1998-06-16	1998-08-12	Merck Sharp & Dohme	Chemical synthesis
GB9816897D0 (en) *	1998-08-04	1998-09-30	Merck Sharp & Dohme	Therapeutic use
AU1230000A (en) *	1998-10-30	2000-05-22	Merck & Co., Inc.	Linear process for the preparation of a morpholine compound
JP2002528546A (ja) *	1998-10-30	2002-09-03	メルクエンドカムパニーインコーポレーテッド	２−（ｒ）−（１−（ｒ）−（３，５−ビス（トリフルオロメチル）フェニル）エトキシ−４−（（５−ジメチルアミノメチル）−１，２，３−トリアゾル−４−イル）メチル）−３−（ｓ）−（４−フルオロフェニル）モルホリン化合物の製造方法
EP1035115B1 (de) *	1999-02-24	2004-09-29	F. Hoffmann-La Roche Ag	4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
IL144851A0 (en)	1999-02-24	2002-06-30	Hoffmann La Roche	3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
IL144717A0 (en)	1999-02-24	2002-06-30	Hoffmann La Roche	Phenyl-and pyridinyl derivatives
US6291465B1 (en)	1999-03-09	2001-09-18	Hoffmann-La Roche Inc.	Biphenyl derivatives
JO2308B1 (en)	1999-05-31	2005-09-12	اف. هوفمان- لاروش أيه جي‏	Derivatives of phenylpyrmidine
TW550258B (en)	1999-05-31	2003-09-01	Hoffmann La Roche	4-phenyl-pyrimidine derivatives
WO2001032656A1 (en) *	1999-10-29	2001-05-10	Merck & Co., Inc.	Polymorphic form of a tachykinin receptor antagonist
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
DK1246806T3 (da)	1999-11-03	2008-06-16	Amr Technology Inc	Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin
DE60006340T2 (de) *	1999-11-29	2004-09-09	F. Hoffmann-La Roche Ag	2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid
US6452001B2 (en)	2000-05-25	2002-09-17	Hoffmann-La Roche Inc.	Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
US6482829B2 (en)	2000-06-08	2002-11-19	Hoffmann-La Roche Inc.	Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
AR030284A1 (es)	2000-06-08	2003-08-20	Merck & Co Inc	Proceso para la sintesis de (2r, 2-alfa-r,3a) -2-[1-(3,5-bis(trifluorometil) fenil) etoxi]-3-(4-fluorofenil)-1,4-oxazina; dicho compuesto y sus formas polimorficas
AU2001269749A1 (en) *	2000-06-09	2001-12-24	Merck And Co., Inc.	Trans-glycosidation process for the synthesis of (2r, 2-alpha-r, 3a)-2-(1-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-3-(4-fluorophenyl)-1,4-oxazine
MXPA03000275A (es)	2000-07-11	2004-12-13	Albany Molecular Res Inc	Nuevas tetrahidroisoquinolinas substituidas con 4-fenilo y su uso terapeutico.
PT1303490E (pt)	2000-07-14	2008-09-04	Hoffmann La Roche	Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
TWI287003B (en)	2000-07-24	2007-09-21	Hoffmann La Roche	4-phenyl-pyridine derivatives
TWI259180B (en)	2000-08-08	2006-08-01	Hoffmann La Roche	4-Phenyl-pyridine derivatives
GB0020721D0 (en) *	2000-08-22	2000-10-11	Merck Sharp & Dohme	Therapeutic agents
YU39503A (sh)	2000-11-22	2006-05-25	F. Hoffmann-La Roche Ag.	Derivati pirimidina
US6642226B2 (en)	2001-02-06	2003-11-04	Hoffman-La Roche Inc.	Substituted phenyl-piperidine methanone compounds
RU2299729C2 (ru) *	2001-07-16	2007-05-27	Орто-Макнейл Фармасьютикал, Инк.	Карбаматные соединения для применения для предотвращения или лечения невропатической боли и боли, связанной с кластерной и мигреневой головной болью
US6849624B2 (en)	2001-07-31	2005-02-01	Hoffmann-La Roche Inc.	Aromatic and heteroaromatic substituted amides
US6638981B2 (en)	2001-08-17	2003-10-28	Epicept Corporation	Topical compositions and methods for treating pain
AR039625A1 (es) *	2002-04-18	2005-03-02	Merck & Co Inc	Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona
HRP20050664A2 (en) *	2003-01-31	2006-12-31	F. Hoffmann - La Roche Ag	NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-A(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE
RU2228752C1 (ru) *	2003-03-21	2004-05-20	Государственный научный центр - Институт биофизики	Фармацевтическая композиция, содержащая ондансетрон и бензамид
ES2291891T3 (es)	2003-07-03	2008-03-01	F. Hoffmann-La Roche Ag	Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia.
US7288658B2 (en) *	2003-07-15	2007-10-30	Hoffmann-La Roche Inc.	Process for preparation of pyridine derivatives
ES2246687B2 (es)	2004-02-11	2006-11-16	Miguel Muñoz Saez	Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
UA91341C2 (ru)	2004-07-15	2010-07-26	Амр Текнолоджи, Інк.	Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
CA2592605C (en)	2004-12-27	2010-12-07	Eisai R&D Management Co., Ltd.	Method for stabilizing anti-dementia drug
ES2329827T3 (es)	2005-02-22	2009-12-01	F. Hoffmann-La Roche Ag	Antagonistas de nk1.
CA2602445C (en)	2005-03-23	2013-08-20	F.Hoffmann-La Roche Ag	Metabolites for nk-i antagonists for emesis
ATE550019T1 (de)	2005-05-17	2012-04-15	Merck Sharp & Dohme	Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
US7956050B2 (en)	2005-07-15	2011-06-07	Albany Molecular Research, Inc.	Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ATE453384T1 (de)	2005-09-23	2010-01-15	Hoffmann La Roche	Neue dosierformulierung
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
WO2007039883A2 (en) *	2005-10-05	2007-04-12	Ranbaxy Laboratories Limited	Process for preparation of aprepitant
RU2392277C2 (ru) *	2005-12-28	2010-06-20	Асино Фарма Аг	Способ получения рацемического небиволола
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
AU2007300627B2 (en)	2006-09-22	2012-02-16	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt)	2007-01-10	2022-01-25	Msd Italia S.R.L.	Compostos de fórmula i e seus usos
US8093268B2 (en)	2007-01-24	2012-01-10	Glaxo Group Limited	Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
AU2008233662B2 (en)	2007-04-02	2012-08-23	Msd K.K.	Indoledione derivative
DE602008001983D1 (de)	2007-04-20	2010-09-09	Hoffmann La Roche	Pyrrolidinderivate als doppelte nk1/nk3-rezeptorenantagonisten
WO2009002495A1 (en)	2007-06-27	2008-12-31	Merck & Co., Inc.	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2010535733A (ja)	2007-08-07	2010-11-25	エフ．ホフマン−ラロシュアーゲー	Ｎｋ３受容体アンタゴニストとしてのピロリジンアリールエーテル
WO2009104080A2 (en)	2008-02-20	2009-08-27	Targia Pharmaceuticals	Cns pharmaceutical compositions and methods of use
US8598184B2 (en)	2008-03-03	2013-12-03	Tiger Pharmatech	Protein kinase inhibitors
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (de)	2009-04-01	2012-09-19	Merck Sharp & Dohme	Hemmer der akt-aktivität
CN102595902B (zh)	2009-05-12	2015-04-29	阿尔巴尼分子研究公司	7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
JP5739415B2 (ja)	2009-05-12	2015-06-24	ブリストル−マイヤーズスクウィブカンパニー	（Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
ES2446971T3 (es)	2009-05-12	2014-03-11	Albany Molecular Research, Inc.	Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
CA2777043C (en)	2009-10-14	2015-12-15	Schering Corporation	Substituted piperidines that increase p53 activity and the uses thereof
US8487102B2 (en)	2010-04-20	2013-07-16	Hoffmann-La Roche Inc.	Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
EP2584903B1 (de)	2010-06-24	2018-10-24	Merck Sharp & Dohme Corp.	Neue heterozyklische verbindungen als erk-hemmer
CN103068980B (zh)	2010-08-02	2017-04-05	瑟纳治疗公司	使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
ES2376564B1 (es)	2010-08-12	2013-01-24	Manuel Vicente Salinas Martín	Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
RU2745848C2 (ru)	2010-08-17	2021-04-01	Сирна Терапьютикс, Инк.	ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de)	2010-09-01	2016-11-02	Merck Sharp & Dohme Corp.	Indazolderivate als erk-hemmer
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en)	2010-12-21	2012-06-28	Schering Corporation	Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en)	2011-04-21	2012-10-26	Piramal Healthcare Limited	A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (de)	2011-10-27	2018-04-04	Merck Sharp & Dohme Corp.	Neue verbindungen als erk-hemmer
US20150297613A1 (en)	2011-12-13	2015-10-22	Servicio Andaluz De Salud	Use of agents that alter the peritumoral environment for the treatment of cancer
EP3919620A1 (de)	2012-05-02	2021-12-08	Sirna Therapeutics, Inc.	Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
CA2882950A1 (en)	2012-09-28	2014-04-03	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
SMT201700595T1 (it)	2012-11-28	2018-03-08	Merck Sharp & Dohme	Composizioni e metodi per trattare il cancro
WO2014100065A1 (en)	2012-12-20	2014-06-26	Merck Sharp & Dohme Corp.	Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en)	2013-01-30	2014-08-07	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as hdm2 inhibitors
ES2493693B1 (es)	2013-02-11	2015-07-07	Servicio Andaluz De Salud	Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
WO2015034925A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Circular polynucleotides
ES2541870B1 (es)	2013-12-27	2016-05-12	Servicio Andaluz De Salud	Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
US20160324881A1 (en) *	2013-12-30	2016-11-10	Oncoprevent Gmbh	Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer
TW201613888A (en)	2014-09-26	2016-04-16	Helsinn Healthcare Sa	Crystalline forms of an NK-1 antagonist
US10005803B2 (en)	2015-10-06	2018-06-26	Helsinn Healthcare Sa	Crystalline forms of fosnetupitant
HRP20200196T1 (hr)	2016-06-06	2020-05-01	Helsinn Healthcare Sa	Fiziološki balansirane injektabilne formulacije fosnetupitanta
US10975084B2 (en)	2016-10-12	2021-04-13	Merck Sharp & Dohme Corp.	KDM5 inhibitors
WO2019094312A1 (en)	2017-11-08	2019-05-16	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
EP3706742B1 (de)	2017-11-08	2023-03-15	Merck Sharp & Dohme LLC	Prmt5-inhibitoren
WO2020033282A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
EP3833667B1 (de)	2018-08-07	2024-03-13	Merck Sharp & Dohme LLC	Prmt5-inhibitoren
CA3108388A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2534915B1 (fr) *	1982-10-26	1985-10-25	Lafon Labor	Nouveaux derives de 2-(phenoxymethyl)-morpholine, utilisation en therapeutique et procede de preparation
CA2112397A1 (en) *	1991-08-20	1993-03-04	Raymond Baker	Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
CA2099233A1 (en) *	1992-06-29	1993-12-30	Conrad P. Dorn	Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) *	1993-12-17	1999-12-22	Merck & Co Inc	Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112778A0 (en) *	1994-03-04	1995-05-26	Merck & Co Inc	Substituted heterocycles, their preparation and pharmaceutical compositions containing them

1994
- 1994-12-23 IL IL11213494A patent/IL112134A/xx not_active IP Right Cessation
- 1994-12-23 DE DE69434991T patent/DE69434991T2/de not_active Expired - Fee Related
- 1994-12-23 RU RU96116158/04A patent/RU2131426C1/ru not_active IP Right Cessation
- 1994-12-23 ES ES95904621T patent/ES2164758T3/es not_active Expired - Lifetime
- 1994-12-23 WO PCT/GB1994/002819 patent/WO1995018124A1/en not_active Ceased
- 1994-12-23 EP EP04076888A patent/EP1462450B1/de not_active Expired - Lifetime
- 1994-12-23 DE DE69434063T patent/DE69434063D1/de not_active Expired - Lifetime
- 1994-12-23 JP JP7517856A patent/JP3071467B2/ja not_active Expired - Lifetime
- 1994-12-23 AT AT04076888T patent/ATE364606T1/de not_active IP Right Cessation
- 1994-12-23 BR BR9408442A patent/BR9408442A/pt not_active Application Discontinuation
- 1994-12-23 AT AT95904621T patent/ATE207917T1/de not_active IP Right Cessation
- 1994-12-23 HU HU9601801A patent/HU221139B1/hu not_active IP Right Cessation
- 1994-12-23 CN CN94194722A patent/CN1067683C/zh not_active Expired - Fee Related
- 1994-12-23 DK DK95904621T patent/DK0737192T3/da active
- 1994-12-23 SK SK839-96A patent/SK283070B6/sk unknown
- 1994-12-23 EP EP95904621A patent/EP0737192B1/de not_active Expired - Lifetime
- 1994-12-23 US US08/663,201 patent/US5612337A/en not_active Expired - Fee Related
- 1994-12-23 PL PL94315182A patent/PL181214B1/pl not_active IP Right Cessation
- 1994-12-23 AT AT01200308T patent/ATE278687T1/de not_active IP Right Cessation
- 1994-12-23 CZ CZ19961898A patent/CZ288176B6/cs not_active IP Right Cessation
- 1994-12-23 KR KR1019960703426A patent/KR100286412B1/ko not_active Expired - Fee Related
- 1994-12-23 CA CA002178219A patent/CA2178219C/en not_active Expired - Fee Related
- 1994-12-23 DE DE69428913T patent/DE69428913T2/de not_active Expired - Fee Related
- 1994-12-23 EP EP01200308A patent/EP1099702B1/de not_active Expired - Lifetime
- 1994-12-23 NZ NZ277839A patent/NZ277839A/en unknown
- 1994-12-23 SG SG1996000578A patent/SG52217A1/en unknown
1995
- 1995-03-20 TW TW084102683A patent/TW449588B/zh active
1996
- 1996-06-06 BG BG100644A patent/BG62616B1/bg unknown
- 1996-06-19 LV LVP-96-197A patent/LV11687B/lv unknown
- 1996-06-28 NO NO962749A patent/NO307090B1/no unknown
2000
- 2000-01-18 JP JP2000009217A patent/JP2000219629A/ja active Pending

Also Published As

Publication number	Publication date
SK83996A3 (en)	1996-11-06
CA2178219A1 (en)	1995-07-06
ES2164758T3 (es)	2002-03-01
DE69434063D1 (de)	2004-11-11
IL112134A0 (en)	1995-03-15
JP2000219629A (ja)	2000-08-08
PL181214B1 (pl)	2001-06-29
HUT75872A (en)	1997-05-28
CN1067683C (zh)	2001-06-27
SK283070B6 (sk)	2003-02-04
LV11687A (lv)	1997-02-20
PL315182A1 (en)	1996-10-14
US5612337A (en)	1997-03-18
LV11687B (en)	1997-10-20
EP1099702B1 (de)	2004-10-06
EP0737192A1 (de)	1996-10-16
CA2178219C (en)	2005-03-22
BG100644A (bg)	1997-03-31
HU9601801D0 (en)	1996-09-30
AU1322395A (en)	1995-07-17
DK0737192T3 (da)	2001-11-26
WO1995018124A1 (en)	1995-07-06
CZ189896A3 (en)	1996-12-11
NO307090B1 (no)	2000-02-07
RU2131426C1 (ru)	1999-06-10
BG62616B1 (bg)	2000-03-31
ATE364606T1 (de)	2007-07-15
SG52217A1 (en)	1998-09-28
EP1462450A1 (de)	2004-09-29
NZ277839A (en)	1998-01-26
DE69434991T2 (de)	2008-03-06
CN1139927A (zh)	1997-01-08
JPH09507484A (ja)	1997-07-29
ATE207917T1 (de)	2001-11-15
HU221139B1 (en)	2002-08-28
EP0737192B1 (de)	2001-10-31
ATE278687T1 (de)	2004-10-15
NO962749D0 (no)	1996-06-28
NO962749L (no)	1996-08-28
DE69428913D1 (de)	2001-12-06
KR100286412B1 (ko)	2001-04-16
TW449588B (en)	2001-08-11
AU685209B2 (en)	1998-01-15
EP1099702A1 (de)	2001-05-16
DE69434991D1 (de)	2007-07-26
DE69428913T2 (de)	2002-05-29
JP3071467B2 (ja)	2000-07-31
BR9408442A (pt)	1997-08-05
EP1462450B1 (de)	2007-06-13
CZ288176B6 (en)	2001-05-16

Legal Events

Date	Code	Title
2000-06-01	FF	Patent granted
2000-08-31	KB	Patent renewed
2001-06-14	KB	Patent renewed
2005-09-25	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
IL112134A0 (en)	1995-03-15	Substituted morpholine derivatives, their preparation and pharmaceutical compositions containing them
DE68914793D1 (de)	1994-05-26	Chinazolinon-Derivate.
MY129540A (en)	2007-04-30	Quinazoline derivatives, pharmaceutical compositions containing them processes for their preparation and their use in the production of an antiangiogenic and/or vascular permeability reducing effect
NZ330868A (en)	2000-01-28	4-phenoxy, phenylthio or phenylamino substituted quinazoline derivatives ane medicaments useful as VEGF inhibitors
AU8794291A (en)	1992-05-21	New oxazolopyridine derivatives, processes for preparing these and pharmaceutical compositions containing them
LU91362I2 (fr)	2007-11-12	Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA)
NO173139C (no)	1993-11-03	Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-aminopyrimidinonderivater
HU9400250D0 (en)	1994-05-30	Quinoline-or quinazoine derivatives process fop producing them and pharmaceutical compositions containing them
AU534470B2 (en)	1984-02-02	Paromomycin derivatives
DE69300318D1 (de)	1995-09-07	Flavonderivate.
DK0784973T3 (da)	2002-03-18	Quinoxalinderivater til behandling af tinnitus
MY105852A (en)	1995-01-30	New 2-methoxycarbonyl substituted n, n'' -di- (trimethoxybenzoyl) piperazines, process for preparing the same and therapeutical compounds containing them.